跳转至内容
Merck
所有图片(1)

文件

R0654

Sigma-Aldrich

Reveromycin A

solid, suitable for cell culture, BioReagent

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C36H52O11
CAS号:
134615-37-5
分子量:
660.79
MDL號碼:
MFCD00912537
分類程式碼代碼:
12352207
PubChem物質ID:
24899342
NACRES:
NA.76

product name

Reveromycin A, solid

生物源

Streptomyces sp.

品質等級

200

形狀

solid

分子量

660.79 g/mol

包裝

pkg of 100 μg

顏色

tan

溶解度

DMF: soluble
DMSO: soluble
ethanol: soluble
ethyl acetate: soluble
methanol: soluble
soluble

抗生素活性譜

fungi

作用方式

protein synthesis | interferes

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

[H][C@]1(C\C=C(C)\C=C\[C@H](O)[C@@H](C)\C=C\C(O)=O)O[C@]2(CC[C@@H]1C)CC[C@@](CCCC)(OC(=O)CCC(O)=O)[C@@]([H])(O2)\C=C\C(C)=C\C(O)=O

InChI

1S/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1

InChI 密鑰

ZESGNAJSBDILTB-OXVOKJAASA-N

生化／生理作用

It is an epidermal growth factor (EGF) and eukaryotic cell growth inhibitor.
Reveromycin A is a polyketide antibiotic from Streptomyces sp. Epidermal growth factor (EGF) inhibitor; apoptosis inducer; G1 phase cell cycle inhibitor having antiproliferative behavior against human cell lines KB and K562 as well as antifungal activity.

分析報告

Avoid acidic conditions.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

M Tanaka et al.
Journal of dental research, 91(8), 771-776 (2012-06-08)
In osteoprotegerin-deficient (OPG-/-) mice, osteoclast activity causes bone resorption to outpace bone formation, leading to the development of severe osteoporosis. Such mice are therefore useful for investigating the alveolar bone of patients with osteoporosis. Reveromycin A (RM-A) was recently identified
H Koshino et al.
The Journal of antibiotics, 45(9), 1420-1427 (1992-09-01)
Reveromycins A, B, C and D are new group inhibitors of the mitogenic activity of epidermal growth factor (EGF), produced by Streptomyces sp. Reveromycins are novel polyketide type antibiotics which have two terminal carboxylic groups, a spiroketal, a succinate and
Shunji Takahashi et al.
Nature chemical biology, 7(7), 461-468 (2011-06-07)
Spiroacetal compounds are ubiquitous in nature, and their stereospecific structures are responsible for diverse pharmaceutical activities. Elucidation of the biosynthetic mechanisms that are involved in spiroacetal formation will open the door to efficient generation of stereospecific structures that are otherwise
Koji Hiraoka et al.
Cancer science, 99(8), 1595-1602 (2008-08-30)
Attention has recently focused on the critical role of inflammatory responses in the tumor stroma that provide favorable conditions for cancer-cell growth and invasion/metastasis. In particular, macrophages recruited into the tumor stroma and activated, known as tumor-associated macrophages, are suggested
Mariana El Sous et al.
Organic letters, 6(17), 3001-3004 (2004-08-28)
The asymmetric total synthesis of (-)-reveromycin A is described. The key steps involved a Lewis acid catalyzed inverse electron demand hetero-Diels-Alder reaction followed by hydroboration/oxidation to afford the spiroketal core 4 in a highly stereoselective manner and introduction of the
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门